(NASDAQ: TVTX) Travere Therapeutics's forecast annual revenue growth rate of 28.26% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 99.61%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.58%.
Travere Therapeutics's revenue in 2025 is $435,827,000.On average, 16 Wall Street analysts forecast TVTX's revenue for 2025 to be $45,972,671,059, with the lowest TVTX revenue forecast at $42,386,620,193, and the highest TVTX revenue forecast at $51,200,539,126. On average, 16 Wall Street analysts forecast TVTX's revenue for 2026 to be $63,135,252,824, with the lowest TVTX revenue forecast at $50,856,070,667, and the highest TVTX revenue forecast at $75,419,803,321.
In 2027, TVTX is forecast to generate $82,280,541,356 in revenue, with the lowest revenue forecast at $59,071,419,732 and the highest revenue forecast at $107,098,375,419.